The Cross-Border Biotech Blog

Biotechnology, Health and Business in Canada, the United States and Worldwide

Teva Decides Not to Wait for U.S. Biosimilars Legislation

In Beni’s post earlier this week on Biosimilars, he identified two major challenges to introducing follow-on biologics into the North American market: technical proficiency, and the absence of a regulatory regime.

Based on the approval of Teva’s biosimilar version of Neupogen in the EU last September, Teva has evidently cleared the first hurdle (and their joint venture with Lonza means their technical capabilities will only increase).

Yesterday, Teva announced that they were not waiting for a Biosimilars regime to be enacted before entering the U.S. market, and instead will take on the extra cost of filing a full BLA for their version of the biologic.

Does this mean we don’t need a biosimilars regime to get biosimilars to market?  Teva itself takes a different position.

Bookmark and Share

About these ads

3 responses to “Teva Decides Not to Wait for U.S. Biosimilars Legislation

  1. Pingback: Wednesday Brain Dump: March 11, 2009 « The Cross-Border Biotech Blog

  2. Pingback: Top 10 Cross-Border Biotech Blog Posts of 2009 « The Cross-Border Biotech Blog

  3. Pingback: Biotech Trends Update: Teva’s BLA for Neupoval is Accepted at the FDA « The Cross-Border Biotech Blog

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

Follow

Get every new post delivered to your Inbox.

Join 126 other followers